



**Nexstim Plc**  
("Nexstim" or the "Company")

**Publishing of Nexstim Plc 2014 Full Year Results**

***Helsinki, 4 February 2015 at 1:00 pm***

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, will announce its full year results for the year ended 31 December 2014 on Thursday 26 February 2015.

A conference call for analysts will take place at 15:00 EET on Thursday 26 February 2015 which will be hosted by Janne Huhtala, Chief Executive Officer, and Mikko Karvinen, Chief Financial Officer, who will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:

Helsinki: 0923195187

Stockholm: 0850336434

London: 08006940257

US: 16315107498

The call ID number is 80666514.

NEXSTIM PLC

Janne Huhtala, Chief Executive Officer

**For further information please visit [www.nexstim.com](http://www.nexstim.com) or contact:**

**Nexstim**

Janne Huhtala, Chief Executive Officer

+358 40 8615046

[janne.huhtala@nexstim.com](mailto:janne.huhtala@nexstim.com)

**UB Capital Oy (Certified Adviser)**

+358 9 2538 0225

**Consilium Strategic Communications**

+44 (0)20 3709 5700

Mary-Jane Elliott

Amber Bielecka

Ivar Milligan

Laura Thornton

[nexstim@consilium-comms.com](mailto:nexstim@consilium-comms.com)

**About Nexstim Plc**

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke



therapy called Navigated Brain Therapy (NBT<sup>®</sup>). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT<sup>®</sup> and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit [www.nexstim.com](http://www.nexstim.com).